期刊文献+

抗凝治疗对非瓣膜性心房颤动患者纤溶指标的动态影响

Effects of anticoagulant therapy on alteration of fibrinolysis parameters in patients with nonvalvular atrial fibrillation
原文传递
导出
摘要 目的:探讨纤溶因素在非瓣膜性心房颤动(房颤)患者高凝状态形成中的作用及抗凝治疗早期纤溶指标浓度的变化趋势。方法:应用酶联免疫吸附(ELISA)法分别测定窦性心律组(窦律组,27例)及房颤组(25例)患者抗凝治疗各时间点(1d、7d、1个月、2个月)组织型纤溶酶原激活物抑制剂-1(PAI-1)、D-二聚体(D-dimer)浓度和INR值。分析两组患者PAI-1和D-dimer浓度的差异、该指标随抗凝治疗时间的变化趋势及PAI-1、D-dimer和INR三者之间的相关性。结果:①房颤组PAI-1和D-dimer水平均明显高于窦律组;②PAI-1和D-dimer浓度在抗凝治疗各时间点均差异有统计学意义(均P<0.05),PAI-1浓度随抗凝治疗各时间点下降百分比分别为7%、18%及31%,D-dimer浓度分别下降19%、34%及43%;③房颤组PAI-1浓度在抗凝治疗1个月、2个月时与窦律组比较均差异有统计学意义(均P<0.05),D-dimer浓度治疗7d、1个月时均差异有统计学意义(均P<0.05);④INR≤2.0较INR>2.0组PAI-1和D-dimer均值较高(均P<0.05)。相关分析发现PAI-1、D-dimer和INR之间均呈显著负相关(r值分别为-0.263、-0.443,P值分别为0.010、0.000),PAI-1和D-dimer之间呈显著正相关(r=0.468,P=0.000)。结论:低纤溶状态可能是非瓣膜性房颤患者高凝状态形成的重要原因;抗凝治疗可有效快速改善房颤患者的低纤溶状态。 Objective:To explore the role of fibrinolysis system in the formation of hypercoagulable state with nonvalvular atrial fibrillation (NVAF) patients and investigate the variation tendency of PAI-1 and D-dimer levels along with the anticoagulant therapy. Method: Patients were divided into NVAF group (n=25) and control group (sinus rhythm with age matched hypertensive patients, n= 27). ELISA method was used to detect the plasma lev els of PAI-I and Ddimer. The difference of PAI 1 , D-dimer levels in two groups, the variation tendency of the two indexes along with anticoagulant therapy, and the correlation among PAI 1, D-dimcr and INR were analyzed. Result:(1)The levels of PA1-1 and Ddimer in NVAF group were higher than those in control group (both P〈 0.05). (2)The plasma levels of PAI-1 and D-dimer significant changed at each time points (the 1st day, 7th day, 1st month, 2nd month) (all P〈0.05). The decreased percentage of PAI-1 concentration were 7%, 18% and 31%, respectively; while D-dimer were 19%, 34% and 43%. (3)The variations of PAI-1 level at 1st month and 2nd month were different between control group and NVAF group (both P〈0.05), the variations of D dimer lev el at 7thdayand 1st month were different between control group and NVAFgroup (both P〈0. 05). (4)PAI 1 and D-dimer levels were higher in INR≤2.0 group than those in INR〉2.0 group. PAI-1, D dimer and INR levels were negatively correlated (r were =0. 263, 0.,143; P were 0.010, 0.000, respectively), while PAI-1 and Ddimer were positively correlated (r= 0. 468, P= 0. 000). Conclusion: Low fibrinolysis state is an important factor in the formation of hypercoagulable state in NVAF. Anticoagulant therapy can improve the fibrinolysis state in NVAF patients quickly and effectively.
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2013年第3期183-186,共4页 Journal of Clinical Cardiology
关键词 心房颤动 非瓣膜性 组织型纤溶酶原激活物抑制剂-1 D-二聚体 atrial fibrillation, nonvauvular plasminogen activator inhibitor-l I〉dimer
  • 相关文献

参考文献15

  • 1MARIN ORTUNO F, ROI.DAN SCHII.LING V, MAR- CO VERA P, et al. Improvement in fibrinolyticfunction following anticoagulant treatment in chronic rtheumatic at rial fibrillation[J]. Rev Esp Cardion, 1999,52 : 25- 30.
  • 2李曦,谢英,赵瑞祥,张维君,温绍君,周玉杰,张妍,程秀琴,张文,彭新界,王龙华,刘洁琳,郭永和.阿司匹林或华法林治疗对非瓣膜病持续性心房颤动患者凝血-纤溶指标影响及安全性[J].临床心血管病杂志,2007,23(10):754-758. 被引量:9
  • 3DE BON() D. Significance of raised plasma concentra tions of tissue-type plasminogen activator and plas minogen activator inhibitor in patients at risk from is chaemic heart disease[J].Br Heart J,1994,71:504- 507.
  • 4HAMSTER A. Hemostatic function and coronary ar tery disease[J]. N EnglJ Med,1995,332:667-668.
  • 5MITUSCH R, SIEMENS H J, GARBE M, el al. Detection of a hypercoagulable state in nonvalvular at rial fibrillation and the effect of anticoagulant therapy [J]. Thromb Haemost,1996,75:219-223.
  • 6ROLDAN V, MARIN F, MARCO P, et al. Antico- agulant therapy modifies fibrinolytic dysfunction in chronic atrial fibrillationEJ2. Haemostasis, 2000,30: 219-224.
  • 7吴俊,于贵杰,许俊堂.非瓣膜性心房颤动高凝状态指标及抗栓治疗监测[J].中国医药导刊,2006,8(4):266-269. 被引量:5
  • 8LI-SAW HEE F I., BLANN A D, I.IP G Y. Effects of fixed low dose warfarin, aspirin-warfarin combina- tion therapy, and dose adjusted warfarin on thrombo- genesis in chronic atrial fibrillation[J]. Stroke, 2000, 31 :828-833.
  • 9许俊堂,胡大一.非瓣膜病性心房颤动的抗栓疗法[J].中华心血管病杂志,2001,29(2):126-128. 被引量:50
  • 10MAHE I, DROUET I., CHASSANY O, et al. D-di- mer: a characteristic of the coagulation state of each patient with chronic atrial fibrillation [J]. Thromb Res,2002,107:1-6.

二级参考文献56

  • 1胡大一,杨进刚.心房颤动的现代观点 (1)我国心房颤动流行概况和危害[J].中国循环杂志,2004,19(5):323-324. 被引量:40
  • 2刘明 ,沈玉祥 ,袁建军 ,翟亚萍 ,商保军 .血小板激活及内皮损伤血液标志物对心房颤动血栓栓塞危险性的评价[J].临床心血管病杂志,2005,21(6):341-343. 被引量:13
  • 3FUSTER V,RYDEN L E,AANNOM D S,et al.ACC/ AHA/ ESC guidelines for the management of patients with atrial fibrillation[J].JACC,2006,27:1979-2030.
  • 4GO A S,HYLEK E M,PHILLIPS K A,et al.Prevalence of diagnosed atrial fibrillation in adults:national implications for rhythm management and stroke prevention:the anticoagulation and risk factors in atrial fibrillation(ATRIA) study[J].JAMA,2001,285:2370-2375.
  • 5Risk factor for stroke and efficacy of antithrombotic therapy in atrial fibrillation.Analysis of pooled data from five randomized controlled trials[J].Arch Intern Med,1994,154:1449-1457.
  • 6ALBERS G W,DALEN J E,LAUPACIS A.Antithrombotic therapy in atrial fibrillation[J].Chest,2001,119:194-206.
  • 7GLAZER N L,DUBLIN S,SMITH N L,et al.Newly detected atrial fibrillation and compliance with antithrombotic guidelines[J].Arch Intern Med,2007,167:246-252.
  • 8LIM L Y,CHONG V H,RAJENDRAN N,et al.A cross-sectional study of the anticoagulation clinic in RIPAS[J].Thromb Thrombolysis,2009,140-145.
  • 9MCBRIDE D,BRUGGENJURGEN B,ROLL S,et al.Anticoagulation treatment for the reduction of stroke in atrial fibrillation:a cohort study to examine the gap between guidelines and routine medical practice[J].Thromb Thrombolysis,2007,24:65-72.
  • 10FIHN S D,CALLAHAN C M,MARTIN D C,et al.The risk for and severity of bleeding complications in elderly patients treated with warfarin.The national consortium of anticoagulation clinics[J].Ann Intern Med,1996,124:970-979.

共引文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部